William Saway, MD
Internal Medicine · Columbia, MDNPI 1780675652
Payments from drug & device makers
What this record shows
28 manufacturers reported payments, led by Midmark Corporation at 52.5% of the total. Reporting peaked in 2023 at $2,680 and has fallen 73.3% since, to $717 in 2025. Among internal medicine clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $35.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Midmark Corporation$3K
- Lilly USA, LLC$404
- AstraZeneca$341
- Pfizer$262
- Amgen$220
- Novo Nordisk$211
- plus $915 from 22 others
Across 44 payments — averaging $6585.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$97K
- Visby Medical, Inc.$54K
- Sanofi$48K
- Gen-probe, Inc.$45K
- AstraZeneca$19K
- BD$9K
- plus $18K from 3 others
What the payments were for
- Travel & lodging$2,42749%
- Food & beverage$2,52751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Midmark Corporation | 2 | $2,602 |
| Lilly USA, LLC | 24 | $404 |
| AstraZeneca | 19 | $341 |
| Pfizer | 19 | $262 |
| Amgen(2 entities) | 14 | $220 |
| Novo Nordisk | 12 | $211 |
| Johnson & Johnson | 7 | $138 |
| Merck | 7 | $100 |
| Boehringer Ingelheim | 5 | $82 |
| Sanofi Pasteur Inc. | 5 | $79 |
| GSK | 4 | $79 |
| Radius Health, Inc. | 2 | $52 |
| Kyowa Kirin, Inc. | 2 | $43 |
| Exact Sciences | 1 | $34 |
| Gilead | 1 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Medtronic(2 entities) | 2 | $30 |
| Abbott | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Flowonix Medical Incorporated | 1 | $24 |
| Philips North America LLC | 1 | $23 |
| Bayer | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Optinose US, Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $13 |
How this compares
$4,954 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 43 | $58,316 |
| OzempicSemaglutide | 32 | $50,301 |
| JanuviaSitagliptin Phosphate | 37 | $35,766 |
| JardianceEmpagliflozin | 27 | $35,756 |
| XareltoRivaroxaban | 14 | $22,792 |
| Atorvastatin Calcium | 509 | $7,787 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $4,411 |
| Rosuvastatin Calcium | 136 | $3,467 |
| SynthroidLevothyroxine Sodium | 42 | $3,373 |
| Losartan Potassium | 240 | $2,589 |
| Tamsulosin Hcl | 113 | $2,541 |
| Amlodipine Besylate | 295 | $2,310 |
| Pregabalin | 22 | $2,308 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,224 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $262 | $58,31643 claims |
| Novo NordiskOzempic | $211 | $50,30132 claims |
| MerckJanuvia | $100 | $35,76637 claims |
| Boehringer IngelheimJardiance | $82 | $35,75627 claims |
| Johnson & JohnsonXarelto | $138 | $22,79214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Columbia
- Mark CorriereColumbia$402K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
- Matthew MintzBethesda$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.